Sanofi's Chief Digital Officer Emmanuel Frenehard had a thought that he just couldn't shake: how can Sanofi extend the ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune ...

Zacks Research increased their FY2024 EPS estimates for shares of Sanofi in a report issued on Wednesday, November 13th.

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Sanofi (SNY) has released an update. Don't Miss our Black Friday Offers: Sanofi’s Sarclisa received a positive recommendation from the EMA’s CHMP for treating newly diagnosed multiple myeloma patients ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.